GGGemma Grau Gómez

Gemma Grau Gómez

*This is an algorithmically generated author record based on publicly available information.

Gemma Grau Gómez has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Angeles Jaen

    Research Unit, Fundació, Docència i Recerca Mútua Terrassa, Terrassa, ESP

    2 shared publications
  • David Clemente

    Internal Medicine, Fundació Assistencial Mútua Terrassa, Terrassa, ESP

    2 shared publications
  • Emma Padilla

    Microbiology Department, Catlab, Fundació Assistencial Mútua Terrassa, Terrassa, ESP

    2 shared publications
  • Helena Monzón Camps

    Internal Medicine, Fundació Assistencial Mútua Terrassa, Terrassa, ESP

    2 shared publications
  • Siena Molina

    Internal Medicine, Fundació Assistencial Mútua Terrassa, Terrassa, ESP

    2 shared publications
  • Xavier Martínez Lacasa

    Internal Medicine, Fundació Assistencial Mútua Terrassa, Terrassa, ESP

    2 shared publications

Latest Publications

  • Open Access

    Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Cohort of Healthcare Workers

    by Gemma Grau Gómez, Xavier Martínez Lacasa, Angeles Jaen, Judith Vidal Martínez, Emma Padilla, David Clemente, Siena Molina, Ales Chlouba, Susana González, Helena Monzón Camps

    In this 13-month follow-up study, we examined a cohort of vaccinated healthcare workers without prior SARS-CoV-2 infection to assess the humoral and cellular response to the BNT162b2 mRNA COVID-19 vaccine over time. We measured median immunoglobulin G and lymphocyte subpopulation levels after the first and second doses, at five months post-second dose, and before and after the third dose. Our findings evinced a remarkable initial cellular and humoral response to each vaccine dose, although a progressive decline suggests the potential need for long-term booster doses. Age analysis showed significantly higher immunoglobulin G levels in the younger group after the first dose administration, although these differences were not maintained in the following doses. Preserving cellular immunity could assure long-lasting protection against SARS-CoV-2 infection.

  • Open Access

    Serological response to COVID-19 pneumonia and increasing severity over 18 months in a prospective cohort of hospitalized patients

    by Gemma Grau Gómez, Xavier Martínez Lacasa, Roser Costa, Bienvenido Barreiro, Miguel Leal, Emma Padilla, Pepa Pérez, Marc Garreta, Judith Vidal, Angeles Jaen, et al.

    In this study, we present an 18-month serological follow-up of 294 patients with COVID-19 pneumonia. The aim was to assess the dynamics of serological response and its correlation with clinical worsening, as well as to describe clinical worsening determinants. Results of the study showed an early immunoglobulin M response, which clearly diminished starting at 4 months, but nonetheless, a small group of patients remained positive. As for immunoglobulin G, levels were higher up to 6 months in patients who presented clinical worsening during hospitalization. High titers of the immunoglobulin were maintained in all patients during follow-up, which would indicate that humoral immunity due to infection is long-lasting. Male sex, presence of myalgias and extensive radiological affectation were significantly correlated with clinical worsening.